Biologic Excipients Market Size is projected to witness a commendable upsurge from 2022 to 2028. This is a result of the significant usage of excipients in the development of novel therapies, and their ability to enhance the solubility of active pharmaceutical ingredients, among other benefits. In addition, the potential use of biologic medications to target specific parts of the immune system to treat diseases like psoriatic arthritis will further proliferate industry expansion over the foreseeable future. Biologics refer to therapeutic preparations produced via biotechnology and other cutting-edge methods in microorganisms, animal cells, plant cells, and other living organisms. Excipients or additives play a major role in stabilization during storage and processing, as biologics are inherently unstable and are susceptible to degradation by physical and chemical factors.
Rapid evolution of drug delivery technologies and the high prevalence of autoimmune, inflammatory diseases are some of the factors augmenting the biologic excipients market size through 2022-2028. As per the CDC’s data, nearly 1 in 4 U.S. adults are diagnosed with arthritis, which could escalate the deployment of biologics ingredients for use as anti-rheumatic drugs. The robust demand for parenteral drugs, especially during the coronavirus pandemic, will also generate opportunities for market growth, as a majority of biologics uses the parenteral route of administration.
Biologic excipients market from the inorganic product segment is expected to record an appreciable revenue by 2028, considering the high physical and chemical stability of calcium phosphate and its compatibility with a wide range of active pharmaceutical ingredients. Moreover, the ability of this product type to function as a hydrophilic porous carrier to boost the oral bioavailability of the low water-soluble drugs will further fuel the segmental expansion in the years ahead. Based on formulation type, the topical formulation segment will account for a major market share over the coming years. Increased prevalence of psoriasis among U.S. adults is a major factor driving usage of topical biologics in psoriasis and other immune-mediated diseases treatment.
On the regional front, the Asia Pacific biologic excipients market is set to amass considerable profits by 2028. This is on account of the rising advancement in AI technology and its potential application in the drug discovery and development process in emerging economies like China. The growing burden of cancer in South Korea will also augment the requirement of biopharma excipients, as research related to leukemia and other cancerous diseases has shifted focus towards the use of biologic excipients.
Some of the key players in the biologic excipients market include Colorcon Inc. (BPSI Holdings), Croda International, Kerry Group PLC, BASF SE, Evonik Industries AG (Rag-Stiftung), Meggle USA, Ashland, Roquette Frères, and Dupont De Nemours, Inc., among others. Strategic product launches, mergers, acquisitions, and business expansions are key initiatives being undertaken by these companies to gain a competitive edge over rivals in the global market. For instance, in August 2021, Croda International Plc announced the expansion of its Mill Hall excipients facility, with an objective to exclusively produce high-purity pharma ingredients, including solid oral doses, biologics, topicals, and vaccines.
Despite the unprecedented impacts of the COVID-19 outbreak on the supply chain of essential pharma ingredients during its peak, the need for biologics, advanced therapeutics, and vaccines has increased considerably. In May 2021, Pfizer Inc. and BioNTech SE initiated a BLA (Biologics License Application) with the U.S. FDA for the approval of an mRNA coronavirus vaccine for use in individuals aged 16 years and older. Developments such as these are anticipated to assert a positive influence on the biologic excipients industry over the forthcoming years.
Market, By Product
Market, By Functionality
Market, By Formulation Type
The above information is provided for the following regions and countries: